SEC Filing Summary for John Gill's Stock Options

This filing details a grant of 48,800 stock options to John Gill, a director at Altimmune, Inc. The options were granted on May 1, 2026, under the company's non-employee director compensation policy. These options carry an exercise price of $2.82 and are set to expire on May 1, 2036. The vesting schedule indicates that the options will become exercisable in equal monthly installments over the 12 months following May 1, 2026, contingent upon Gill's continued service. Following the grant, Gill holds 48,800 shares underlying these options.